2 months Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates Zacks
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 293.75% and 24.38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?